Activate and resist: L576P-KIT in GIST

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastrointestinal stromal tumors (GIST) are often driven by KIT or PDGFRA mutations.
• The L576P KIT mutation is rare in GIST but associated with aggressive disease and poor response to imatinib therapy.
• Understanding the molecular mechanisms of imatinib resistance is crucial for GIST treatment.

Observation:

• This study investigated the L576P KIT mutation in GIST using histological, immunohistochemical, biochemical, and molecular analyses.
• In silico studies estimated the binding affinities of wild-type, L576P/KIT, and Delta559/KIT to imatinib.
• Despite clinical response, histological evaluation showed minimal tumor regression in patients with the L576P mutation.

Findings:

• KIT was expressed and activated in GISTs with the L576P mutation, independent of secondary mutations or gene alterations.
• In silico modeling demonstrated that L576P/KIT has significantly lower affinity for imatinib compared to wild-type KIT and the sensitive Delta559/KIT.
• L576P/KIT showed approximately two-fold reduced sensitivity to imatinib compared to wild-type KIT.

Implications:

• The L576P KIT mutation confers intrinsic resistance to imatinib in GIST, explaining the limited histological response observed.
• These findings highlight the importance of molecular profiling for predicting treatment outcomes in GIST.
• Further research into alternative therapeutic strategies for GIST patients with the L576P mutation is warranted.